Argenx To Acquire FDA Priority Review Voucher - Quick Facts
30/11 07:12
(RTTNews) - argenx SE (ARGX) announced an agreement to acquire a FDA Priority Review Voucher for $102 million. The company expects to redeem the PRV for a future marketing application for efgartigimod, its neonatal Fc receptor blocker....